{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:41:50Z","timestamp":1761864110442,"version":"build-2065373602"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"vor","delay-in-days":46,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007054","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"TEVA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Brazilian Journal of Infectious Diseases"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.bjid.2020.04.004","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T16:40:52Z","timestamp":1588092052000},"page":"96-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of in vitro activity of ceftolozane\u2013tazobactam against recent clinical bacterial isolates from Brazil \u2013 the EM200 study"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3471-1786","authenticated-orcid":false,"given":"Felipe Francisco","family":"Tuon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliette","family":"Cieslinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suellen da Silva","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando Brand\u00e3o","family":"Serra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina Della-Negra de","family":"Paula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bjid.2020.04.004_bib0235","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/14740338.2018.1488962","article-title":"Antimicrobial resistance and treatment: an unmet clinical safety need","volume":"17","author":"Bassetti","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.bjid.2020.04.004_bib0240","unstructured":"Centers of Disease Control and Prevention (CDC). About antimicrobial resistance. Available at: https:\/\/www.cdc.gov\/drugresistance\/about.html"},{"key":"10.1016\/j.bjid.2020.04.004_bib0245","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1378\/chest.14-2171","article-title":"Antimicrobial resistance in hospital-acquired gram-negative bacterial infections","volume":"147","author":"Mehrad","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.bjid.2020.04.004_bib0250","first-page":"2018","article-title":"Rethinking how antibiotics are prescribed","volume":"321","author":"Tamma","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.bjid.2020.04.004_bib0255","series-title":"Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics","first-page":"7","author":"World Health Organization (WHO)","year":"2017"},{"key":"10.1016\/j.bjid.2020.04.004_bib0260","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1309\/LMNIJE31EDC1WAMP","article-title":"Molecular epidemiology and drug susceptibility of Pseudomonas aeruginosa strains isolated from burn patients","volume":"41","author":"Salimi","year":"2010","journal-title":"Lab Med"},{"key":"10.1016\/j.bjid.2020.04.004_bib0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.212527","article-title":"How to manage Pseudomonas aeruginosa infections","volume":"7","author":"Bassetti","year":"2018","journal-title":"Drugs Cont"},{"key":"10.1016\/j.bjid.2020.04.004_bib0270","article-title":"Ceftolozane\/tazobactam for the treatment of serious P. aeruginosa infections: a multicenter nationwide clinical experience","author":"Bassetti","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bjid.2020.04.004_bib0275","first-page":"83","article-title":"Boletim de Seguran\u00e7a do Paciente e Qualidade em Servi\u00e7os de Sa\u00fade no 16: Avalia\u00e7\u00e3o dos indicadores nacionais das Infec\u00e7\u00f5es Relacionadas \u00e0 Assist\u00eancia \u00e0 Sa\u00fade (IRAS) e Resist\u00eancia microbiana do ano de 2016","volume":"16","author":"Brasil","year":"2016","journal-title":"ANVISA - Seguran\u00e7a Do Paciente E Qual Em Servi\u00e7os Sa\u00fade"},{"key":"10.1016\/j.bjid.2020.04.004_bib0280","first-page":"825","article-title":"Ceftolozane\/Tazobactam: a new option in the treatment of complicated gram-negative infections","volume":"39","author":"Sorbera","year":"2014","journal-title":"P&T"},{"key":"10.1016\/j.bjid.2020.04.004_bib0285","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.diagmicrobio.2015.10.008","article-title":"Emerging trends in epidemiology and management of infections caused by carbapenem-resistant Enterobacteriaceae","volume":"85","author":"Martirosov","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.bjid.2020.04.004_bib0290","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bjid.2017.06.008","article-title":"Ceftolozane\u2013tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013\u20132015)","volume":"21","author":"Pfaller","year":"2017","journal-title":"Brazilian J Infect Dis"},{"year":"2015","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards","author":"Clinical Laboratory Standards Institute (CLSI)","key":"10.1016\/j.bjid.2020.04.004_bib0295"},{"year":"2017","series-title":"Performance standards for antimicrobial susceptibility testing \u2013 twenty-seventh informational supplement","author":"Clinical Laboratory Standards Institute (CLSI)","key":"10.1016\/j.bjid.2020.04.004_bib0300"},{"key":"10.1016\/j.bjid.2020.04.004_bib0305","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. EUCAST clinical breakpoints. Available at: http:\/\/www.eucast.org\/clinical_breakpoints\/"},{"key":"10.1016\/j.bjid.2020.04.004_bib0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01589-17","article-title":"Genomics and susceptibility profiles of extensively drug-resistant Pseudomonas aeruginosa isolates from Spain","volume":"61","author":"del Barrio-Tofi\u00f1o","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2020.04.004_bib0315","article-title":"Antimicrobial activity of ceftolozane\u2013tazobactam tested against gram-negative contemporary (2015\u20132017) isolates from hospitalized patients with pneumonia in US medical centers","author":"Carvalhaes","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.bjid.2020.04.004_bib0320","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.diagmicrobio.2018.05.002","article-title":"Ceftolozane\/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients","volume":"92","author":"Finklea","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.bjid.2020.04.004_bib0325","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3343\/alm.2017.37.2.174","article-title":"Susceptibility of ceftolozane\u2013tazobactam and ceftazidime-avibactam against a collection of \u03b2-lactam-resistant gram-negative bacteria","volume":"37","author":"Gonzalez","year":"2017","journal-title":"Ann Lab Med"},{"key":"10.1016\/j.bjid.2020.04.004_bib0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01350-17","article-title":"In vitro comparison of ceftolozane\u2013tazobactam to traditional beta-lactams and ceftolozane\u2013tazobactam as an alternative to combination antimicrobial therapy for Pseudomonas aeruginosa","volume":"61","author":"Goodlet","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2020.04.004_bib0335","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/jac\/dkx136","article-title":"Activity of ceftolozane\/tazobactam against surveillance and \u201cproblem\u201d Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bjid.2020.04.004_bib0340","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jinf.2014.04.004","article-title":"Ceftolozane\/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012)","volume":"69","author":"Sader","year":"2014","journal-title":"J Infect"},{"key":"10.1016\/j.bjid.2020.04.004_bib0345","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ijantimicag.2017.06.024","article-title":"In-vitro activity of ceftolozane\/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany","volume":"51","author":"Seifert","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bjid.2020.04.004_bib0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00465-17","article-title":"Ceftolozane\u2013tazobactam activity against Pseudomonas aeruginosa clinical isolates from US hospitals: report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015","volume":"61","author":"Shortridge","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bjid.2020.04.004_bib0355","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.diagmicrobio.2018.05.011","volume":"92","author":"Shortridge","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.bjid.2020.04.004_bib0360","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ijantimicag.2015.07.004","article-title":"In vitro activity of ceftolozane\/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: results of the CENIT study","volume":"46","author":"Tato","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bjid.2020.04.004_bib0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2019.01.015","article-title":"Activity of ceftolozane\u2013tazobactam and comparators when tested against Gram-negative isolates collected from paediatric patients in the United States and Europe during 2012\u20132016 as part of a global surveillance programme","author":"Shortridge","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bjid.2020.04.004_bib0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2019.02.004","article-title":"Activity of ceftolozane\u2013tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered in Intensive Care Units in Spain: the SUPERIOR multicentre study","author":"Garc\u00eda-Fern\u00e1ndez","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bjid.2020.04.004_bib0375","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/joim.12342","article-title":"Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control","volume":"277","author":"T\u00e4ngd\u00e9n","year":"2015","journal-title":"J Intern Med"},{"year":"2017","author":"BRASIL","key":"10.1016\/j.bjid.2020.04.004_bib0380"},{"year":"2018","series-title":"Mechanisms and detection of antimicrobial resistance. Principles and practice of pediatric infectious diseases","author":"Alby","key":"10.1016\/j.bjid.2020.04.004_bib0385"},{"key":"10.1016\/j.bjid.2020.04.004_bib0390","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.diagmicrobio.2018.08.007","article-title":"What's new in the treatment of multidrug-resistant gram-negative infections?","volume":"93","author":"Mo","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.bjid.2020.04.004_bib0395","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/avibactam and ceftolozane\/tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2020.04.004_bib0400","first-page":"846","article-title":"Defining the role of novel \u03b2-lactam agents that target carbapenem-resistant gram-negative organisms","volume":"45","author":"Tamma","year":"2019","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.bjid.2020.04.004_bib0405","first-page":"1","article-title":"Carbapenem resistance: a review","volume":"6","author":"Codjoe","year":"2017","journal-title":"Med Sci"},{"key":"10.1016\/j.bjid.2020.04.004_bib0410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0155914","article-title":"Clinical and molecular epidemiology of multidrug-resistant P. aeruginosa carrying aac(6\u2032)-ib-cr, qnrs1 and blaspm genes in Brazil","volume":"11","author":"Araujo","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.bjid.2020.04.004_bib0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0176774","article-title":"Molecular epidemiological survey of bacteremia by multidrug resistant Pseudomonas aeruginosa: the relevance of intrinsic resistance mechanisms","volume":"12","author":"Dantas","year":"2017","journal-title":"PLoS One"},{"year":"2015","series-title":"Estudo epidemiol\u00f3gico molecular da resist\u00eancia aos carbapen\u00eamicos em Pseudomonas aeruginosa isoladas de sangue: produ\u00e7\u00e3o de \u03b2-lactamases, perda de porina OprD e hiperexpress\u00e3o de bombas de efluxo","author":"Dantas","key":"10.1016\/j.bjid.2020.04.004_bib0420"},{"key":"10.1016\/j.bjid.2020.04.004_bib0425","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1590\/0074-02760160116","article-title":"Mechanisms of carbapenem resistance in endemic Pseudomonas aeruginosa isolates after an SPM-1 metallo-\u03b2-lactamase producing strain subsided in an intensive care unit of a teaching hospital in Brazil","volume":"111","author":"Cacci","year":"2016","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.bjid.2020.04.004_bib0430","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.diagmicrobio.2012.04.007","article-title":"Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008\u20132010)","volume":"73","author":"Gales","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.bjid.2020.04.004_bib0435","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1586\/14787210.2013.811924","article-title":"Current status of carbapenemases in Latin America","volume":"11","author":"Maya","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.bjid.2020.04.004_bib0440","first-page":"216","article-title":"Antimicrobial susceptibility of Gram-negative bacteria in Brazilian hospitals: the MYSTIC Program Brazil 2003","volume":"9","author":"Kiffer","year":"2005","journal-title":"Brazilian J Infect Dis"},{"key":"10.1016\/j.bjid.2020.04.004_bib0445","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1517\/14740338.2015.1088520","article-title":"The safety of polymyxin antibiotics","volume":"14","author":"Kelesidis","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.bjid.2020.04.004_bib0450","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cir934","article-title":"What Is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression","volume":"54","author":"Florescu","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bjid.2020.04.004_bib0455","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1128\/JCM.02357-14","article-title":"In vitro activity of ceftolozane\u2013tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum \u03b2-lactamases","volume":"52","author":"Estabrook","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.bjid.2020.04.004_bib0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.01858-17","article-title":"Activity of ceftolozane\u2013tazobactam and ceftazidime-avibactam against beta-lactam-resistant Pseudomonas aeruginosa isolates","volume":"61","author":"Humphries","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["The Brazilian Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867020300313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1413867020300313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T15:55:21Z","timestamp":1761407721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1413867020300313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S1413867020300313"],"URL":"https:\/\/doi.org\/10.1016\/j.bjid.2020.04.004","relation":{},"ISSN":["1413-8670"],"issn-type":[{"type":"print","value":"1413-8670"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of in vitro activity of ceftolozane\u2013tazobactam against recent clinical bacterial isolates from Brazil \u2013 the EM200 study","name":"articletitle","label":"Article Title"},{"value":"The Brazilian Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bjid.2020.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Sociedade Brasileira de Infectologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}